Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous cytokine-induced killer cells (Guangxi Zhuang Autonomous Region People's Hospital)
- Development stage
- Unknown
- Lead developer
- Guangxi Zhuang Autonomous Region People's Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous cytokine-induced killer (CIK) cells are an ex vivo expanded population of immune effector cells, primarily T lymphocytes, used as a form of adoptive cell immunotherapy. These cells are generated from a patient's own peripheral blood mononuclear cells (PBMCs) through a standardized culture process involving stimulation with interferon-gamma (IFN-γ), interleukin-2 (IL-2), and anti-CD3 monoclonal antibodies. CIK cells are characterized by a CD3+CD56+ phenotype and possess potent, non-MHC-restricted cytolytic activity against a broad range of tumor cells, primarily mediated by the NKG2D receptor. The People's Hospital of Guangxi Zhuang Autonomous Region has evaluated these cells as a maintenance immunotherapy for patients with advanced (Stage IIIb/IV) nonsquamous non-small cell lung cancer (NSCLC) to prolong progression-free survival and improve quality of life following initial chemotherapy.
- Other names
- CIK cellsautologous CIK cellscytokine-induced killer cells
Beyond the preview
Go deeper on autologous cytokine-induced killer cells (Guangxi Zhuang Autonomous Region People's Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous cytokine-induced killer cells (Guangxi Zhuang Autonomous Region People's Hospital).